S&P 500   4,585.61 (+0.80%)
DOW   36,125.48 (+0.20%)
QQQ   390.37 (+1.38%)
AAPL   194.22 (+0.99%)
MSFT   370.35 (+0.42%)
META   326.56 (+2.87%)
GOOGL   137.24 (+5.55%)
AMZN   146.01 (+1.03%)
TSLA   241.15 (+0.74%)
NVDA   464.53 (+2.09%)
NIO   7.47 (-3.61%)
BABA   72.23 (+1.04%)
AMD   128.52 (+10.02%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.71 (+0.79%)
CGC   0.71 (+2.48%)
GE   119.20 (-0.51%)
DIS   92.40 (+0.98%)
AMC   6.83 (+0.59%)
PFE   28.72 (-0.24%)
PYPL   58.48 (-1.76%)
XOM   98.31 (-0.81%)
S&P 500   4,585.61 (+0.80%)
DOW   36,125.48 (+0.20%)
QQQ   390.37 (+1.38%)
AAPL   194.22 (+0.99%)
MSFT   370.35 (+0.42%)
META   326.56 (+2.87%)
GOOGL   137.24 (+5.55%)
AMZN   146.01 (+1.03%)
TSLA   241.15 (+0.74%)
NVDA   464.53 (+2.09%)
NIO   7.47 (-3.61%)
BABA   72.23 (+1.04%)
AMD   128.52 (+10.02%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.71 (+0.79%)
CGC   0.71 (+2.48%)
GE   119.20 (-0.51%)
DIS   92.40 (+0.98%)
AMC   6.83 (+0.59%)
PFE   28.72 (-0.24%)
PYPL   58.48 (-1.76%)
XOM   98.31 (-0.81%)
S&P 500   4,585.61 (+0.80%)
DOW   36,125.48 (+0.20%)
QQQ   390.37 (+1.38%)
AAPL   194.22 (+0.99%)
MSFT   370.35 (+0.42%)
META   326.56 (+2.87%)
GOOGL   137.24 (+5.55%)
AMZN   146.01 (+1.03%)
TSLA   241.15 (+0.74%)
NVDA   464.53 (+2.09%)
NIO   7.47 (-3.61%)
BABA   72.23 (+1.04%)
AMD   128.52 (+10.02%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.71 (+0.79%)
CGC   0.71 (+2.48%)
GE   119.20 (-0.51%)
DIS   92.40 (+0.98%)
AMC   6.83 (+0.59%)
PFE   28.72 (-0.24%)
PYPL   58.48 (-1.76%)
XOM   98.31 (-0.81%)
S&P 500   4,585.61 (+0.80%)
DOW   36,125.48 (+0.20%)
QQQ   390.37 (+1.38%)
AAPL   194.22 (+0.99%)
MSFT   370.35 (+0.42%)
META   326.56 (+2.87%)
GOOGL   137.24 (+5.55%)
AMZN   146.01 (+1.03%)
TSLA   241.15 (+0.74%)
NVDA   464.53 (+2.09%)
NIO   7.47 (-3.61%)
BABA   72.23 (+1.04%)
AMD   128.52 (+10.02%)
T   17.08 (+0.83%)
F   10.86 (+1.59%)
MU   73.71 (+0.79%)
CGC   0.71 (+2.48%)
GE   119.20 (-0.51%)
DIS   92.40 (+0.98%)
AMC   6.83 (+0.59%)
PFE   28.72 (-0.24%)
PYPL   58.48 (-1.76%)
XOM   98.31 (-0.81%)

Novo Resources Corp. (NVO.V) Stock Price, News & Analysis (CVE:NVO)

C$2.38
-0.01 (-0.42%)
(As of 12/31/2020)
Compare
Today's Range
C$2.37
▼
C$2.44
50-Day Range
C$2.38
▼
C$2.38
52-Week Range
C$1.41
▼
C$4.16
Volume
311,570 shs
Average Volume
273,252 shs
Market Capitalization
C$548.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NVO stock logo

About Novo Resources Corp. (NVO.V) Stock (CVE:NVO)

Novo Resources Corp., together with its subsidiaries, engages in evaluating, acquiring, and exploring natural resource properties in Canada, Australia, and the United States. It primarily explores for gold deposits. The company primarily focuses on the Egina and Beatons Creek projects in the Pilbara region of Western Australia. It also holds interest in the Mt. Elsie project that consists of three exploration licenses covering an area of approximately 19 square kilometers located in the north-east of Nullagine, Western Australia. The company was formerly known as Galliard Resources Corp. and changed its name to Novo Resources Corp. in June 2011. Novo Resources Corp. was incorporated in 2009 and is headquartered in Vancouver, Canada.

NVO Stock Price History

NVO Stock News Headlines

December 6, 2023 | msn.com
Novo Nordisk’s Wegovy beats older obesity meds in drug adherence
December 6, 2023 | americanbankingnews.com
Novo Resources Corp. (NVO.V) (CVE:NVO) Shares Down 0.4%
December 7, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
December 1, 2023 | msn.com
Compounded Wegovy Matters Sink Novo Nordisk (NYSE:NVO)
November 30, 2023 | msn.com
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
November 30, 2023 | msn.com
Novo Nordisk sues Florida pharmacies for selling compounded Wegovy with impurities
November 27, 2023 | msn.com
Novo Nordisk CEO: Willing to be "flexible" on Wegovy pricing schemes - FT
November 24, 2023 | msn.com
Novo Nordisk (NYSE:NVO) Set to Introduce Wegovy in Asia
December 7, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
November 24, 2023 | msn.com
Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch
November 23, 2023 | marketwatch.com
Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France
November 14, 2023 | msn.com
Novo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'
November 14, 2023 | msn.com
Novo Nordisk's Wegovy may not secure Medicare approval for heart - Deutsche Bank
November 14, 2023 | finance.yahoo.com
Successful RC Drill Program Completed at Nunyerry North
November 13, 2023 | msn.com
Novo Nordisk's Wegovy reduces risk of serious heart problems by 20%, study shows
November 13, 2023 | msn.com
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
November 13, 2023 | barrons.com
European Stocks Climb, Novo Nordisk Gains on Wegovy Data
November 10, 2023 | msn.com
Novo Nordisk, maker of Ozempic and Wegovy, to invest more than $6 billion to expand production
November 9, 2023 | msn.com
People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions
November 3, 2023 | msn.com
Novo Nordisk flags big 2024 sales boost despite Wegovy curbs
November 2, 2023 | msn.com
Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month
November 2, 2023 | msn.com
Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
November 2, 2023 | msn.com
Wegovy could receive expanded FDA approval within six months, Novo Nordisk says
November 1, 2023 | msn.com
Novo Nordisk Reports Earnings Thursday. It’s All About Weight-Loss Drugs.
November 1, 2023 | reuters.com
Exclusive: Novo hires FUJIFILM unit to help make Wegovy weight-loss drug - source
October 16, 2023 | msn.com
Novo Nordisk to buy hypertension drug candidate for up to $1.3B
October 16, 2023 | msn.com
Novo Nordisk Buys Hypertension Drug in $1.3 Billion Deal
See More Headlines
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Resources Corp. (NVO.V) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Industrial Metals & Minerals
Sub-Industry
N/A
Sector
Basic Materials
Current Symbol
CVE:NVO
CUSIP
N/A
CIK
N/A
Web
www.novoresources.com
Phone
604-562-4854
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
11.62
Current Ratio
2.78
Quick Ratio
2.57

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.22 per share
Price / Cash Flow
10.77
Book Value
C$1.38 per share
Price / Book
1.72

Miscellaneous

Outstanding Shares
230,354,000
Free Float
N/A
Market Cap
C$548.24 million
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Quinton Todd Hennigh (Age 53)
    Chairman & Pres
    Comp: $364.38k
  • Mr. Robert Humphryson
    CEO & Director
  • Mr. Ronan Sabo-Walsh
    CFO & Corp. Sec.
  • Mr. Leonidas Karabelas (Age 41)
    VP of Corp. Communications
  • Ms. Kas De Luca
    Gen. Mang. of Exploration
  • Mr. Alwin van Roij
    Sr. Exploration Geologist

Key Competitors

View All Competitors

Insiders















NVO Stock Analysis - Frequently Asked Questions

How have NVO shares performed in 2023?

Novo Resources Corp. (NVO.V)'s stock was trading at C$2.38 at the start of the year. Since then, NVO stock has increased by 0.0% and is now trading at C$2.38.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Novo Resources Corp. (NVO.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Resources Corp. (NVO.V) investors own include Pretium Resources (PVG), Ivanhoe Mines (IVN), Pretium Resources (PVG), Gold Standard Ventures (GSV), Harmony Gold Mining (HMY), First Majestic Silver (AG), Yamana Gold (AUY), Barrick Gold (GOLD) and Alexco Resource (AXU).

How do I buy shares of Novo Resources Corp. (NVO.V)?

Shares of NVO stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:NVO) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -